Denny’s Group at Vandy

Clopidogrel Poor Metabolizers

Note: Attached documents contain full case definition and two different control definitions.  One is for controls with 2 years of follow up, the other for controls with 1 year of follow up.  All available controls with 2 years of follow up were used in Vanderbilt's study.  The control population was supplemented by controls with only 1 year of follow up.  At the time of study, many of the available controls had experienced their qualifying events somewhat recently and 2 years had not yet passed for full follow up.

 

Final

Identification of Fibromyalgia Patients in a Rheumatoid Arthritis Cohort

Fibromyalgia has been estimated to affect 12-17% of rheumatoid arthritis patients (1, 2). 

This algorithm was created to identify fibromyalgia patients in a population of rheumatoid arthritis patients. The gold standard used for diagnosis of fibromyalgia was that the treating rheumatologist made a clinical diagnosis of fibromyalgia. Rheumatoid arthritis patients were identified by using a previously validated algorithm (3). 

Algorithm included the following conditions: 

Owner Phenotyping Groups: 
Final

PGx medication risk prediction model

This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences.  This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.  

 

For more information on PREDICT, see http://mydruggenome.org.

Owner Phenotyping Groups: 
Final